Sagent Pharmaceuticals

Facilitating employer and employee
savings with biosimilars

An increased understanding of biosimilars can facilitate their uptake and use, which can then result in notable savings for both employers and employees.

A recent report by the ERISA Industry Committee (ERIC) describes an average savings of approximately $1.5 million for large companies and significant savings for patients when a biosimilar vs a reference product was included in the healthcare plan.1

Appropriate resources that provide education on biosimilars and resolve misconceptions on their use and efficacy can offer a broader understanding to healthcare providers and plan participants.

Information about what a biosimilar is, their value, interchangeability, and other educational resources can be found here:

Overall, key strategies for employers to promote biosimilar uptake and increase savings potential include:2


Improved understanding of biosimilars

Drug utilization management strategies

Inclusion of biosimilars in prescription benefit plans

Appropriate review of biosimilars in pharmacy benefit manager contracts


1. Socal M, Ballreich J, Chyr L, Anderson G. Biosimilar medications � savings opportunities for large employers. ERISA Industry Committee. March 2020. Accessed June 19, 2020.

2. The Segal Group. Employer strategies for use of biosimilar pharmaceuticals. March 2020. Accessed June 19, 2020. 

This email was sent on behalf of the sponsor by HealthEconomics.Com, 1327 Walnut, Jacksonville, FL, 32206.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here, or send your request in writing to the address above.
Read more about our privacy policy here. You may also request a copy in writing using the address above.

To ensure you continue to receive emails from HealthEconomics.Com, please click here.